Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
http://www.priceseries.com/trade/ATRA-Atara-Biotherapeutics-Inc-stock-gains-88-percent-a-Trade-Record-by-priceSeries-2018010420180202.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments